Overview

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

Status:
COMPLETED

Trial end date:
2023-02-13

Target enrollment:

Participant gender:

Summary

Phase I clinical study to investigate the safety and tolerance of therapeutic BCG in postoperative adjuvant therapy in subjects with moderate to high-risk non-muscular invasive bladder cancer (NMIBC)

Phase:

PHASE1

Details

Lead Sponsor:

Chengdu CoenBiotech Co., Ltd

Collaborator:

Hunan Cancer Hospital

Treatments:

Therapeutic Uses